Objectives: The aim of this study was to compare the clinical efficacy and tolerance of polyethylene glycol 3350 (PEG) and lactulose for the treatment of functional constipation in infants and children.
Methods: This randomized, multicenter study covered 12 weeks of treatment and 4 weeks of follow-up of patients with functional constipation. Patients were randomized (central randomization) to receive either PEG or lactulose. The primary end points were the number of defecations per week after 12 weeks of treatment and improvement in stool consistency of at least 2 points in the Bristol scale. The secondary end point was the presence of adverse events. Bowel movements ≥3 per week and stool consistency ≥2 (Bristol scale) were considered as successful treatment.
Results: We enrolled 102 patients (M 57, F 45) aged 3.62 ± 1.42 years and 88 completed the study. At week 12, good clinical outcome was achieved in 98% (PEG) and 90% (lactulose). The PEG group had more defecations per week compared with the lactulose group (7.9 ± 0.6 vs 5.7 ± 0.5, P = 0.008) and both groups had similar frequency of defecation with pain (5% vs 5%, P = 0.9), stool retention (7% vs 10%, P = 057), large volume of stools (30% vs 31%, P = 0.9) and hard stools (7% vs 13%, P = 0.58). There were more patients with side effects in the lactulose group (15 vs 23, P = 0.02), mostly bloating and abdominal pain.
Conclusions: PEG 3350 is more effective and causes fewer side effects than lactulose in the treatment of constipation in infants and children.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MPG.0000000000002192 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Effects of Adding Probiotic, Alone and in Combination With Zinc, to Routine Treatment on Recurrence of Hepatic Encephalopathy, Quality of Life, and Sleep Quality in Patients With Cirrhosis: An Open-Label Randomized Controlled Trial.
Food Sci Nutr
January 2025
Department of Clinical Pharmacy (Pharmacotherapy), Drug Applied Research Center Tabriz University of Medical Sciences Tabriz Iran.
Overt hepatic encephalopathy (OHE) is a common complication of decompensated cirrhosis. This study aimed to assess the effects of probiotic, alone and in combination with zinc, on OHE recurrence, Model for End-stage Liver Disease (MELD) score, ammonia level, health-related quality of life (HRQoL), and sleep quality in patients with cirrhosis. We performed an open-label randomized controlled trial on patients with decompensated cirrhosis with a previous history of OHE.
View Article and Find Full Text PDFLactulose Versus Naloxone for Opioid-Induced Constipation in Intensive Care.
Turk J Pharm Sci
January 2025
Shahid Beheshti University of Medical Sciences Faculty of Medicine, Toxicological Research Center, Excellence Center and Department of Clinical Toxicology, Tehran, Iran.
Objectives: Constipation caused by opioid-induced constipation (OIC) is prevalent among critically poisoned patients and can result in complications that prolong hospitalization and, in rare cases, cause bowel perforatio This research aimed to evaluate the safety and efficacy of lactulose and naloxone in the treatment of OIC in the intensive care unit for poisoning.
Materials And Methods: This was a randomized, double-blind, clinical trial of patients with opioid poisoning who experienced constipation for 14 months. Patients were divided into two groups: one receiving lactulose (30 cc daily) and the other receiving naloxone (8 mg three times a day).
Microbiota transplant for hepatic encephalopathy in cirrhosis: The THEMATIC trial.
J Hepatol
January 2025
Division of Gastroenterology and Hepatology and Center for Immunology, University of Minnesota, Minneapolis, Minnesota, USA.
Background: Preventing hepatic encephalopathy (HE) recurrence in cirrhosis, which is associated with an altered gut-liver-brain axis, is an unmet need. Fecal microbiota transplantation (FMT) is beneficial in phase-1 studies, but route and dose-related questions remain.
Methods: We performed a phase-2 randomized, placebo-controlled, double-blind, clinical trial of capsule and enema FMT in cirrhosis and HE on lactulose and rifaximin.
A smart probe for detection of sugar markers for applications in gastrointestinal barrier dysfunction.
Biosens Bioelectron
December 2024
Bio-Acoustic MEMS in Medicine (BAMM) Laboratory, Canary Center at Stanford, Department of Radiology, Stanford School of Medicine, Stanford University, Palo Alto, CA, 94304, USA. Electronic address:
Article Synopsis
- Gastrointestinal (GI) barrier dysfunction is a critical early indicator of multiple complex diseases, but current testing methods for saccharide molecules used to assess this function are expensive and time-consuming.
- A new one-component system utilizing a naphthyl-pyridine core and boronic acid receptor has been developed for the early detection of saccharide biomarkers like lactulose, which indicates GI barrier issues.
- The innovative design incorporates a scalable 96-well format with gold nanoparticles and combines plasmonics and fluorescence for sensitive lactulose quantification, aiming to create an affordable and portable diagnostic tool for routine GI permeability testing.
Relationship between Quality Practice Metrics and Treatment Outcomes in Hospitalized Cirrhotic Patients.
Asian Pac J Cancer Prev
December 2024
Division of Gastroenterology and Hepatology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University. 681 Samsen Road, Dusit District 10300, Bangkok, Thailand.
Background/aims: Variations in cirrhosis management practices and care quality affect patient prognoses and outcomes. We aimed to evaluate the number of successful cirrhosis care processes and the relationship between the quality statement implementation and clinical outcomes in patients with cirrhosis.
Methods: This retrospective cohort study included hospitalized patients with cirrhosis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!